The clinical benefit of adjuvant chemotherapy for stage II colorectal cancer (CRC) is controversial. This study aimed to explore novel gene signature to predict outcome benefit of postoperative 5-Fu-based therapy in stage II CRC. | A network-based predictive geneexpression signature for adjuvant chemotherapy benefit in stage II colorectal cancer